ArticleRegenerative therapy2026
RAD51 promotes osteogenic differentiation and inhibits DNA damage in osteoporosis though regulating cGAS-STING signaling pathway.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoporosis (OP) represents a metabolic bone disorder characterized by reduced bone density and increased fracture susceptibility, primarily caused by an imbalance between bone resorption and formation. Osteogenic differentiation plays a critical role in OP, as it promotes bone formation processes. RAD51, a crucial gene encoding a protein essential for homologous recombination repair of DNA double-strand breaks, is central to maintaining genomic stability and ensuring accurate DNA repair. Previous investigations conducted by our research team have suggested the involvement of RAD51 in the pathogenesis of OP. The objective of this study was to explore the signaling pathways associated with RAD51. Methods: MC3T3-E1 cells were induced to undergo osteogenic differentiation and exposed to a microgravity environment to simulate OP-like conditions. Furthermore, an ovariectomized (OVX) mouse model was established to mimic OP. Osteogenic differentiation was evaluated through Alizarin Red S staining for calcium deposition and alkaline phosphatase (ALP) staining to assess ALP activity. DNA damage was quantified using the comet assay, while protein expression profiles were analyzed via Western blot. Results: Experimental results showed a significant downregulation of RAD51 expression in OP models. Notably, RAD51 overexpression promoted osteoblast differentiation and mitigated DNA damage in these models. Mechanistic studies further revealed that RAD51 suppresses activation of the cGAS-STING signaling pathway, which has been shown to negatively regulate osteoblast differentiation. In OVX mice, RAD51 overexpression mitigated bone loss, promoted osteoblast differentiation, and reduced DNA damage. Conclusion: RAD51 facilitated osteogenic differentiation and attenuated DNA damage in OP by modulating the cGAS-STING signaling pathway, offering a potential novel therapeutic target for OP treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.